CRSP
CRSP
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
4
$53.00M
Insider Sales
42
$29.51M
Total Volume
$82.51M
73 transactions
Net Activity
+$23.49M
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Moderate accumulation: purchases represent 64% of total transaction value.
- •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Ultra-high accumulation: total purchase value exceeds $10M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$2018.48B total
George Simeon
Dir
$52.22M total
Kulkarni Samarth
CEO
$19.65M total
Prasad Raju
CFO
$5.35M total
Kasinger James R.
GC, Secretary
$2.36M total
Quick Actions
CRSP has an insider buy conviction of 64%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at CRSP (CRSP) engaged in a total of 73 transactions reported via SEC Form 4 filings. Among these, 4 were open-market purchases and 42 were sales. The total volume of insider trading reached $82.51M.
The net insider activity for CRSP shows a net buying bias of $23.49M. This activity represents a 64% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 2.04M shares valued at $2017.99B on Jul 16, 2025.
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base
After gifting stock, the CEO of CRISPR Therapeutics (CRSP) reported holding 211,899 shares directly.
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
FAQs About CRSP Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for CRSP.